LEE011 in patients with malignant rhabdoid tumours and neuroblastoma

• Research type

  Research Study

• Full title

  A Phase 1 multicentre open label dose escalation study of LEE011 in patients with malignant rhabdoid tumours and neuroblastoma

• IRAS ID

  121873

• Contact name

  Andrew Pearson

• Contact email

  Andrew.Pearson@icr.ac.uk

• Sponsor organisation

  Novartis Pharma Services

• Eudract number

  2012-004228-40

• ISRCTN Number

  n/a

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  13/LO/0343

• Date of REC Opinion

  22 Apr 2013

• REC opinion

  Further Information Favourable Opinion